Matthew Campobasso Sells 1,081 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN - Get Free Report) General Counsel Matthew Campobasso sold 1,081 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $12,409.88. Following the transaction, the general counsel now owns 72,641 shares of the company's stock, valued at approximately $833,918.68. This represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Matthew Campobasso also recently made the following trade(s):

• On Wednesday, March 5th, Matthew Campobasso sold 1,695 shares of Enfusion stock. The stock was sold at an average price of $11.38, for a total value of $19,289.10.
• On Tuesday, January 7th, Matthew Campobasso sold 976 shares of Enfusion stock. The stock was sold at an average price of $10.13, for a total value of $9,886.88.

Enfusion Stock Down 0.5 %

NYSE:ENFN traded down $0.06 during mid-day trading on Friday, reaching $11.24. 970,369 shares of the stock were exchanged, compared to its average volume of 1,164,913. The company has a 50 day simple moving average of $10.98 and a 200-day simple moving average of $9.89. The stock has a market capitalization of $1.44 billion, a P/E ratio of 280.95, a P/E/G ratio of 1.85 and a beta of 0.95. Enfusion, Inc. has a 1 year low of $7.83 and a 1 year high of $11.80.

Enfusion (NYSE:ENFN - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The company had revenue of $52.94 million during the quarter, compared to analysts' expectations of $53.98 million. As a group, research analysts predict that Enfusion, Inc. will post 0.06 EPS for the current year.

Remove Ads

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC grew its stake in shares of Enfusion by 7.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company's stock valued at $9,770,000 after purchasing an additional 70,367 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Enfusion by 6.7% in the 3rd quarter. Wellington Management Group LLP now owns 976,296 shares of the company's stock valued at $9,265,000 after purchasing an additional 61,032 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Enfusion by 612.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company's stock valued at $1,974,000 after purchasing an additional 178,821 shares during the last quarter. Barclays PLC grew its stake in shares of Enfusion by 251.4% in the 3rd quarter. Barclays PLC now owns 86,039 shares of the company's stock valued at $817,000 after purchasing an additional 61,554 shares during the last quarter. Finally, PDT Partners LLC purchased a new position in shares of Enfusion in the 3rd quarter valued at approximately $867,000. 81.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. William Blair reissued a "market perform" rating on shares of Enfusion in a research note on Monday, January 13th. Piper Sandler increased their target price on Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research note on Monday, December 23rd. Finally, Stifel Nicolaus increased their target price on Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a research note on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.